{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T17:12:35Z","timestamp":1783444355627,"version":"3.54.6"},"reference-count":90,"publisher":"Elsevier","isbn-type":[{"value":"9780443313967","type":"print"}],"license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025]]},"DOI":"10.1016\/bs.enz.2025.06.009","type":"book-chapter","created":{"date-parts":[[2025,7,23]],"date-time":"2025-07-23T09:46:31Z","timestamp":1753263991000},"page":"319-335","source":"Crossref","is-referenced-by-count":1,"title":["Challenges for developing selective viral protease inhibitors as antiinfectives"],"prefix":"10.1016","member":"78","reference":[{"issue":"5","key":"10.1016\/bs.enz.2025.06.009_bib0001","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1074\/jbc.TM118.004156","article-title":"Proteases: history, discovery, and roles in health and disease","volume":"294","author":"Bond","year":"2019","journal-title":"J. Biol. Chem"},{"issue":"45","key":"10.1016\/bs.enz.2025.06.009_bib0002","doi-asserted-by":"crossref","first-page":"30433","DOI":"10.1074\/jbc.R800035200","article-title":"Proteases: multifunctional enzymes in life and disease","volume":"283","author":"L\u00f3pez-Ot\u00edn","year":"2008","journal-title":"J. Biol. Chem"},{"issue":"5","key":"10.1016\/bs.enz.2025.06.009_bib0003","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.mam.2008.04.003","article-title":"Protease proteomics: revealing protease in vivo functions using systems biology approaches","volume":"29","author":"Doucet","year":"2008","journal-title":"Mol. Aspects Med"},{"issue":"8042","key":"10.1016\/bs.enz.2025.06.009_bib0004","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/s41586-024-08280-5","article-title":"\u03c0-HuB consortium. \u03c0-HuB: the proteomic navigator of the human body","volume":"636","author":"He","year":"2024","journal-title":"Nature"},{"issue":"1","key":"10.1016\/bs.enz.2025.06.009_bib0005","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1111\/j.1399-3054.2011.01536.x","article-title":"N- and C-terminal degradomics: new approaches to reveal biological roles for plant proteases from substrate identification","volume":"145","author":"Huesgen","year":"2012","journal-title":"Physiol. Plant"},{"issue":"6","key":"10.1016\/bs.enz.2025.06.009_bib0006","doi-asserted-by":"crossref","first-page":"831","DOI":"10.2174\/092986712799034824","article-title":"Inhibition of bacterial carbonic anhydrases and zinc proteases: from orphan targets to innovative new antibiotic drugs","volume":"19","author":"Supuran","year":"2012","journal-title":"Curr. Med. Chem"},{"issue":"4","key":"10.1016\/bs.enz.2025.06.009_bib0007","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1002\/med.10007","article-title":"Bacterial protease inhibitors","volume":"22","author":"Supuran","year":"2002","journal-title":"Med Res Rev"},{"issue":"4","key":"10.1016\/bs.enz.2025.06.009_bib0008","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1080\/13543776.2021.1857726","article-title":"Protease inhibitors targeting the main protease and papain-like protease of coronaviruses","volume":"31","author":"Capasso","year":"2021","journal-title":"Expert Opin Ther Pat"},{"issue":"15","key":"10.1016\/bs.enz.2025.06.009_bib0009","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1002\/cmdc.201600220","article-title":"Discovery of HIV type\u20051 aspartic protease hit compounds through combined computational approaches","volume":"11","author":"Xanthopoulos","year":"2016","journal-title":"ChemMedChem"},{"issue":"12","key":"10.1016\/bs.enz.2025.06.009_bib0010","doi-asserted-by":"crossref","first-page":"5784","DOI":"10.1021\/jm300180r","article-title":"Dual inhibitors for aspartic proteases HIV-1 PR and renin: advancements in AIDS-hypertension-diabetes linkage via molecular dynamics, inhibition assays, and binding free energy calculations","volume":"55","author":"Tzoupis","year":"2012","journal-title":"J. Med. Chem"},{"key":"10.1016\/bs.enz.2025.06.009_bib0011","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/bs.enz.2021.09.004","article-title":"Viral proteases: Structure, mechanism and inhibition","volume":"50","author":"Zephyr","year":"2021","journal-title":"Enzymes"},{"issue":"5","key":"10.1016\/bs.enz.2025.06.009_bib0012","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.mam.2008.04.003","article-title":"Protease proteomics: revealing protease in vivo functions using systems biology approaches","volume":"29","author":"Doucet","year":"2008","journal-title":"Mol. Aspects Med"},{"issue":"4","key":"10.1016\/bs.enz.2025.06.009_bib0013","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.tips.2013.02.004","article-title":"Missing the target: matrix metalloproteinase antitargets in inflammation and cancer","volume":"34","author":"Dufour","year":"2013","journal-title":"Trends Pharmacol. Sci"},{"key":"10.1016\/bs.enz.2025.06.009_bib0014","series-title":"Metalloenzymes, From Bench to Bedside","first-page":"239","article-title":"Angiotensin-converting enzyme","author":"Arrighi","year":"2024"},{"issue":"24","key":"10.1016\/bs.enz.2025.06.009_bib0015","doi-asserted-by":"crossref","DOI":"10.3390\/ijms252413320","article-title":"Angiotensin-(1-7) and central control of cardiometabolic outcomes: implications for obesity hypertension","volume":"25","author":"Vernail","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/bs.enz.2025.06.009_bib0016","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/bs.vh.2024.06.004","article-title":"Distribution of the kisspeptin system and its relation with gonadotropin-releasing hormone in the hypothalamus","volume":"127","author":"Dorfman","year":"2025","journal-title":"Vitam. Horm"},{"issue":"2","key":"10.1016\/bs.enz.2025.06.009_bib0017","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.coviro.2013.03.009","article-title":"Viral precursor polyproteins: keys of regulation from replication to maturation","volume":"3","author":"Yost","year":"2013","journal-title":"Curr. Opin. Virol"},{"issue":"1","key":"10.1016\/bs.enz.2025.06.009_bib0018","doi-asserted-by":"crossref","DOI":"10.1002\/rmv.70012","article-title":"Molecular evolution of the h5 and h7 highly pathogenic avian influenza virus haemagglutinin cleavage site motif","volume":"35","author":"Luczo","year":"2025","journal-title":"Rev. Med. Virol"},{"issue":"3","key":"10.1016\/bs.enz.2025.06.009_bib0019","doi-asserted-by":"crossref","first-page":"366","DOI":"10.3390\/v16030366","article-title":"Recent advances on targeting proteases for antiviral development","volume":"16","author":"Borges","year":"2024","journal-title":"Viruses"},{"issue":"7","key":"10.1016\/bs.enz.2025.06.009_bib0020","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1080\/13543776.2020.1760838","article-title":"A deadly spillover: SARS-CoV-2 outbreak","volume":"30","author":"Mori","year":"2020","journal-title":"Expert Opin. Ther. Pat"},{"issue":"5","key":"10.1016\/bs.enz.2025.06.009_bib0021","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1038\/s41389-021-00334-x","article-title":"MMP8 increases tongue carcinoma cell-cell adhesion and diminishes migration via cleavage of anti-adhesive FXYD5","volume":"10","author":"Juurikka","year":"2021","journal-title":"Oncogenesis"},{"issue":"16","key":"10.1016\/bs.enz.2025.06.009_bib0022","doi-asserted-by":"crossref","first-page":"3083","DOI":"10.1007\/s00018-019-03171-9","article-title":"Matrix metalloproteinases in the CNS: interferons get nervous","volume":"76","author":"Chopra","year":"2019","journal-title":"Cell Mol. Life Sci"},{"issue":"3","key":"10.1016\/bs.enz.2025.06.009_bib0023","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1124\/pharmrev.121.000349","article-title":"Matrix Metalloproteinases: From Molecular Mechanisms to Physiology, Pathophysiology, and Pharmacology","volume":"74","author":"de Almeida","year":"2022","journal-title":"Pharmacol. Rev"},{"issue":"2","key":"10.1016\/bs.enz.2025.06.009_bib0024","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-291X(67)80055-X","article-title":"On the size of the active site in proteases. I. Papain","volume":"27","author":"Schechter","year":"1967","journal-title":"Biochem. Biophys. Res. Commun"},{"issue":"26","key":"10.1016\/bs.enz.2025.06.009_bib0025","doi-asserted-by":"crossref","first-page":"2734","DOI":"10.2174\/092986707782360141","article-title":"Inhibitors of HIV-1 protease: current state of the art 10 years after their introduction. From antiretroviral drugs to antifungal, antibacterial and antitumor agents based on aspartic protease inhibitors","volume":"14","author":"Mastrolorenzo","year":"2007","journal-title":"Curr. Med. Chem"},{"issue":"6","key":"10.1016\/bs.enz.2025.06.009_bib0026","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1080\/17460441.2022.2052847","article-title":"Perspectives on the design and discovery of \u03b1-ketoamide inhibitors for the treatment of novel coronavirus: where do we stand and where do we go?","volume":"17","author":"Nocentini","year":"2022","journal-title":"Expert Opin. Drug Discov"},{"key":"10.1016\/bs.enz.2025.06.009_bib0027","series-title":"HCV: The Journey from Discovery to a Cure","first-page":"231","article-title":"Evolution of HCV NS3\/4a protease inhibitors","volume":"1","author":"Liverton","year":"2019"},{"key":"10.1016\/bs.enz.2025.06.009_bib0028","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinorgbio.2021.111386","article-title":"Rowi\u0144ska-\u017byrek M. Peptidomimetics\u2014an infinite reservoir of metal binding motifs in metabolically stable and biologically active molecules","volume":"217","author":"W\u0105t\u0142y","year":"2021","journal-title":"J. Inorg. Biochem"},{"issue":"6","key":"10.1016\/bs.enz.2025.06.009_bib0029","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1002\/ddr.21406","article-title":"Limiting assumptions in the design of peptidomimetics","volume":"78","author":"Marshall","year":"2017","journal-title":"Drug Dev. Res"},{"issue":"21","key":"10.1016\/bs.enz.2025.06.009_bib0030","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.2174\/138161209788682343","article-title":"Modulating proteostasis: peptidomimetic inhibitors and activators of protein folding","volume":"15","author":"Hatahet","year":"2009","journal-title":"Curr. Pharm. Des"},{"issue":"3","key":"10.1016\/bs.enz.2025.06.009_bib0031","doi-asserted-by":"crossref","first-page":"243","DOI":"10.3109\/10717544.2013.878858","article-title":"Strategies for drug delivery to the central nervous system by systemic route","volume":"22","author":"Kasinathan","year":"2015","journal-title":"Drug Deliv"},{"issue":"3","key":"10.1016\/bs.enz.2025.06.009_bib0032","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/s41573-020-00114-z","article-title":"Natural products in drug discovery: advances and opportunities","volume":"20","author":"Atanasov","year":"2021","journal-title":"Nat. Rev. Drug Discov"},{"issue":"7811","key":"10.1016\/bs.enz.2025.06.009_bib0033","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41586-020-2223-y","article-title":"Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors","volume":"582","author":"Jin","year":"2020","journal-title":"Nature"},{"key":"10.1016\/bs.enz.2025.06.009_bib0034","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0028479","article-title":"Yeast based small molecule screen for inhibitors of SARS-CoV","volume":"6","author":"Frieman","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/bs.enz.2025.06.009_bib0035","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/095632020901900402","article-title":"Thiopurine analogue inhibitors of severe acute respiratory syndrome-coronavirus papain-like protease, a deubiquitinating and deISGylating enzyme","volume":"19","author":"Chen","year":"2009","journal-title":"Antivir. Chem. Chemother"},{"key":"10.1016\/bs.enz.2025.06.009_bib0036","doi-asserted-by":"crossref","first-page":"5928","DOI":"10.1016\/j.bmc.2012.07.038","article-title":"Ryu YB. Tanshinones as selective and slow-binding inhibitors for SARS-CoV cysteine proteases","volume":"20","author":"Park","year":"2012","journal-title":"Bioorg. Med. Chem"},{"key":"10.1016\/bs.enz.2025.06.009_bib0037","doi-asserted-by":"crossref","first-page":"2036","DOI":"10.1248\/bpb.b12-00623","article-title":"Diarylheptanoids from Alnus japonica inhibit papain-like protease of severe acute respiratory syndrome coronavirus","volume":"35","author":"Park","year":"2012","journal-title":"Biol. Pharm. Bull"},{"key":"10.1016\/bs.enz.2025.06.009_bib0038","doi-asserted-by":"crossref","first-page":"3051","DOI":"10.1016\/j.bmc.2013.03.027","article-title":"Geranylated flavonoids displaying SARS-CoV papain-like protease inhibition from the fruits of Paulownia tomentosa","volume":"21","author":"Cho","year":"2013","journal-title":"Bioorg. Med. Chem"},{"key":"10.1016\/bs.enz.2025.06.009_bib0039","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1004113","article-title":"Structural Basis for the Ubiquitin-Linkage Specificity and deISGylating activity of SARS-CoV papain-like protease","volume":"10","author":"Ratia","year":"2014","journal-title":"PLoS Pathog"},{"issue":"42","key":"10.1016\/bs.enz.2025.06.009_bib0040","doi-asserted-by":"crossref","first-page":"eabd4596","DOI":"10.1126\/sciadv.abd4596","article-title":"Activity profiling and crystal structures of inhibitor-bound SARS-CoV-2 papain-like protease: A framework for anti-COVID-19 drug design","volume":"6","author":"Rut","year":"2020","journal-title":"Sci. Adv"},{"issue":"4","key":"10.1016\/bs.enz.2025.06.009_bib0041","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1002\/j.1460-2075.1993.tb05774.x","article-title":"Two crystal structures for cathepsin D: the lysosomal targeting signal and active site","volume":"12","author":"Metcalf","year":"1993","journal-title":"EMBO J"},{"issue":"2","key":"10.1016\/bs.enz.2025.06.009_bib0042","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1086\/340729","article-title":"A history of pepsin and related enzymes","volume":"77","author":"Fruton","year":"2002","journal-title":"Q. Rev. Biol"},{"issue":"5440","key":"10.1016\/bs.enz.2025.06.009_bib0043","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1126\/science.286.5440.735","article-title":"Beta-secretase cleavage of Alzheimer\u2019s amyloid precursor protein by the transmembrane aspartic protease BACE","volume":"286","author":"Vassar","year":"1999","journal-title":"Science"},{"issue":"19","key":"10.1016\/bs.enz.2025.06.009_bib0044","doi-asserted-by":"crossref","first-page":"10034","DOI":"10.1073\/pnas.93.19.10034","article-title":"Structure and inhibition of plasmepsin II, a hemoglobin-degrading enzyme from Plasmodium falciparum","volume":"93","author":"Silva","year":"1996","journal-title":"Proc. Natl. Acad. Sci U S A."},{"issue":"1-2","key":"10.1016\/bs.enz.2025.06.009_bib0045","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0167-4838(00)00068-6","article-title":"Enzymic characteristics of secreted aspartic proteases of Candida albicans","volume":"1480","author":"Koelsch","year":"2000","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/bs.enz.2025.06.009_bib0046","series-title":"Antiprotozoal Drug Development and Delivery","first-page":"321","article-title":"Challenges and promises for obtaining new antiprotozoal drugs: What\u2019s going wrong ?","author":"Vermelho","year":"2022"},{"issue":"4","key":"10.1016\/bs.enz.2025.06.009_bib0047","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/135965350200600401","article-title":"Combination of protease inhibitors for the treatment of HIV-1-infected patients: a review of pharmacokinetics and clinical experience","volume":"6","author":"van Heeswijk","year":"2001","journal-title":"Antivir. Ther"},{"issue":"3","key":"10.1016\/bs.enz.2025.06.009_bib0048","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1097\/01.qai.0000182629.74336.4d","article-title":"Once-daily regimen of saquinavir, ritonavir, didanosine, and lamivudine in HIV-infected patients with standard tuberculosis therapy (TBQD Study)","volume":"40","author":"Ribera","year":"2005","journal-title":"J. Acquir. Immune. Defic. Syndr"},{"issue":"1","key":"10.1016\/bs.enz.2025.06.009_bib0049","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1128\/AAC.47.1.118-123.2003","article-title":"Steady-state pharmacokinetics of amprenavir coadministered with ritonavir in human immunodeficiency virus type 1-infected patients","volume":"47","author":"Goujard","year":"2003","journal-title":"Antimicrob. Agents Chemother"},{"issue":"2","key":"10.1016\/bs.enz.2025.06.009_bib0050","first-page":"56","article-title":"Superior virological efficacy of ritonavir-boosted protease inhibitor regimens compared to single protease inhibitor therapy","volume":"8","author":"Lichterfeld","year":"2003","journal-title":"Eur. J. Med. Res"},{"issue":"5","key":"10.1016\/bs.enz.2025.06.009_bib0051","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1007\/s40121-024-00959-6","article-title":"Ritonavir: 25 years' experience of concomitant medication management. A narrative review","volume":"13","author":"Quercia","year":"2024","journal-title":"Infect Dis. Ther"},{"issue":"1","key":"10.1016\/bs.enz.2025.06.009_bib0052","doi-asserted-by":"crossref","first-page":"66","DOI":"10.3390\/arm92010009","article-title":"Clinical effectiveness of ritonavir-boosted nirmatrelvir\u2014a literature review","volume":"92","author":"Paltra","year":"2024","journal-title":"Adv. Respir. Med"},{"issue":"9","key":"10.1016\/bs.enz.2025.06.009_bib0053","article-title":"Nirmatrelvir combined with ritonavir for preventing and treating COVID-19","volume":"9","author":"Reis","year":"2022","journal-title":"Cochr. Database Syst. Rev"},{"key":"10.1016\/bs.enz.2025.06.009_bib0054","series-title":"Advances in Prodrugs, Design and Therapeutic Applications","first-page":"2019","article-title":"Antiviral and antiretroviral prodrugs","author":"Pisano","year":"2025"},{"issue":"10","key":"10.1016\/bs.enz.2025.06.009_bib0055","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1128\/AAC.01089-12","article-title":"Cobicistat boosts the intestinal absorption of transport substrates, including HIV protease inhibitors and GS-7340, in vitro","volume":"56","author":"Lepist","year":"2012","journal-title":"Antimicrob. Agents Chemother"},{"key":"10.1016\/bs.enz.2025.06.009_bib0056","series-title":"Metalloenzymes\u2014From Bench to Bedside","first-page":"9","article-title":"DNA and RNA polymerases","author":"Picarazzi","year":"2024"},{"key":"10.1016\/bs.enz.2025.06.009_bib0057","series-title":"Metalloenzymes\u2014From Bench to Bedside","first-page":"23","article-title":"Reverse transcriptase","author":"Angeli","year":"2024"},{"issue":"4","key":"10.1016\/bs.enz.2025.06.009_bib0058","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1080\/13543776.2021.1880568","article-title":"SARS-CoV-2 RNA-dependent RNA polymerase as a therapeutic target for COVID-19","volume":"31","author":"Vicenti","year":"2021","journal-title":"Expert Opin. Ther. Pat"},{"issue":"7","key":"10.1016\/bs.enz.2025.06.009_bib0059","doi-asserted-by":"crossref","first-page":"4514","DOI":"10.1039\/D0CS01084G","article-title":"Medicinal chemistry strategies for discovering antivirals effective against drug-resistant viruses","volume":"50","author":"Ma","year":"2021","journal-title":"Chem. Soc. Rev"},{"key":"10.1016\/bs.enz.2025.06.009_bib0060","series-title":"HCV: The Journey from Discovery to a Cure","first-page":"261","article-title":"Development and marketing of INCIVEK (Telaprevir; VX-950): a first generation HCV protease inhibitor, in combination with PEGylated interferon and ribavirin","volume":"1","author":"Kwong","year":"2019"},{"key":"10.1016\/bs.enz.2025.06.009_bib0061","series-title":"HCV: The Journey from Discovery to a Cure","first-page":"293","article-title":"Discovery of Boceprevir, a ketoamide-derived HCV NS3 protease inhibitor, for treatment of genotype 1 infections","volume":"1","author":"Venkatraman","year":"2019"},{"key":"10.1016\/bs.enz.2025.06.009_bib0062","series-title":"HCV: The Journey from Discovery to a Cure","first-page":"317","article-title":"The discovery and early clionical evaluation of the HCV NS3\/4a protease inhibitor asunaprevir (BMS-650032)","volume":"1","author":"Meanwell","year":"2019"},{"key":"10.1016\/bs.enz.2025.06.009_bib0063","series-title":"HCV: The Journey from Discovery to a Cure","first-page":"141","article-title":"The discovery of sofosbuvir: A liver-targeted nucleotide prodrug for the treatment and cure of HCV","volume":"1","author":"Sofia","year":"2019"},{"issue":"8","key":"10.1016\/bs.enz.2025.06.009_bib0064","doi-asserted-by":"crossref","first-page":"1778","DOI":"10.1002\/anie.201102762","article-title":"Enhancing protein backbone binding\u2013a fruitful concept for combating drug-resistant HIV","volume":"51","author":"Ghosh","year":"2012","journal-title":"Angew. Chem. Int. Ed. Engl"},{"issue":"3","key":"10.1016\/bs.enz.2025.06.009_bib0065","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1128\/JVI.76.3.1349-1358.2002","article-title":"A potent human immunodeficiency virus type 1 protease inhibitor, UIC-94003 (TMC-126), and selection of a novel (A28S) mutation in the protease active site","volume":"76","author":"Yoshimura","year":"2002","journal-title":"J. Virol"},{"issue":"8","key":"10.1016\/bs.enz.2025.06.009_bib0066","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.3390\/ijms25084376","article-title":"The inhibition of NS2B\/NS3 protease: a new therapeutic opportunity to treat dengue and zika virus infection","volume":"25","author":"Starvaggi","year":"2024","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/bs.enz.2025.06.009_bib0067","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.chembiol.2022.03.007","article-title":"Inhibiting a dynamic viral protease by targeting a non-catalytic cysteine","volume":"29","author":"Hulce","year":"2022","journal-title":"Cell Chem Biol"},{"key":"10.1016\/bs.enz.2025.06.009_bib0068","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105381","article-title":"Allosteric inhibitors of the main protease of SARS-CoV-2","volume":"205","author":"Samrat","year":"2022","journal-title":"Antivi. Res"},{"key":"10.1016\/bs.enz.2025.06.009_bib0069","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2024.110362","article-title":"30 years of HIV therapy: current and future antiviral drug targets","volume":"603","author":"Nuwagaba","year":"2025","journal-title":"Virology"},{"issue":"6","key":"10.1016\/bs.enz.2025.06.009_bib0070","doi-asserted-by":"crossref","first-page":"357","DOI":"10.35772\/ghm.2024.01073","article-title":"HIV-1 protease inhibitors and mechanisms of HIV-1\u2019s resistance","volume":"6","author":"Das","year":"2024","journal-title":"Glob. Health Med"},{"issue":"1","key":"10.1016\/bs.enz.2025.06.009_bib0071","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1186\/s12879-025-10546-w","article-title":"Patient preferences for long-acting HIV treatment: a preference heterogeneity assessment","volume":"25","author":"Saldarriaga","year":"2025","journal-title":"BMC Infect. Dis"},{"issue":"3","key":"10.1016\/bs.enz.2025.06.009_bib0072","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1093\/jac\/dkaf025","article-title":"Question and answers on long-acting therapy with cabotegravir and rilpivirine in people with HIV","volume":"80","author":"Taramasso","year":"2025","journal-title":"J. Antimicrob. Chemother"},{"issue":"3","key":"10.1016\/bs.enz.2025.06.009_bib0073","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/hiv.13748","article-title":"Patient and healthcare provider perceptions and the potential role for a twice-yearly injectable HIV treatment","volume":"26","author":"Alford","year":"2025","journal-title":"HIV Med"},{"key":"10.1016\/bs.enz.2025.06.009_bib0074","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.96617.4","article-title":"Differences in HIV-1 reservoir size, landscape characteristics, and decay dynamics in acute and chronic treated HIV-1 Clade C infection","volume":"13","author":"Reddy","year":"2025","journal-title":"eLife"},{"issue":"1","key":"10.1016\/bs.enz.2025.06.009_bib0075","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1093\/jac\/dkae391","article-title":"Rapid viral suppression using integrase inhibitors during acute HIV-1 infection","volume":"80","author":"McKellar","year":"2025","journal-title":"J. Antimicrob. Chemother"},{"issue":"10","key":"10.1016\/bs.enz.2025.06.009_bib0076","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1016\/j.jiph.2023.08.001","article-title":"Dengue overview: an updated systemic review","volume":"16","author":"Khan","year":"2023","journal-title":"J. Infect. Public Health"},{"key":"10.1016\/bs.enz.2025.06.009_bib0077","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105517","article-title":"Therapeutics for flaviviral infections","volume":"210","author":"Bifani","year":"2023","journal-title":"Antivi. Res"},{"issue":"1","key":"10.1016\/bs.enz.2025.06.009_bib0078","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3390\/v17010001","article-title":"Animal models, therapeutics, and vaccine approaches to emerging and re-emerging flaviviruses","volume":"17","author":"Baric","year":"2024","journal-title":"Viruses"},{"issue":"12","key":"10.1016\/bs.enz.2025.06.009_bib0079","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.3390\/microorganisms12122623","article-title":"West Nile virus: an update focusing on Southern Europe","volume":"12","author":"Carrasco","year":"2024","journal-title":"Microorganisms"},{"issue":"12","key":"10.1016\/bs.enz.2025.06.009_bib0080","doi-asserted-by":"crossref","DOI":"10.1128\/mbio.02946-24","article-title":"Emerging mosquito-borne flaviviruses","volume":"15","author":"Nelson","year":"2024","journal-title":"mBio"},{"issue":"3","key":"10.1016\/bs.enz.2025.06.009_bib0081","doi-asserted-by":"crossref","first-page":"e2535","DOI":"10.1002\/rmv.2535","article-title":"Modulation of immune responses in the central nervous system by Zika virus, West Nile virus, and dengue virus","volume":"34","author":"Wu","year":"2024","journal-title":"Rev. Med. Virol"},{"issue":"4","key":"10.1016\/bs.enz.2025.06.009_bib0082","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.pt.2024.02.004","article-title":"Arbovirus impact on mosquito behavior: the jury is still out","volume":"40","author":"Maire","year":"2024","journal-title":"Trends Parasitol"},{"key":"10.1016\/bs.enz.2025.06.009_bib0083","first-page":"55","article-title":"Development and application of treatment for chikungunya fever","volume":"13","author":"Millsapps","year":"2022","journal-title":"Res. Rep. Trop. Med"},{"issue":"1","key":"10.1016\/bs.enz.2025.06.009_bib0084","doi-asserted-by":"crossref","first-page":"62","DOI":"10.3390\/v17010062","article-title":"Chikungunya: from hypothesis to evidence of increased severe disease and fatalities","volume":"17","author":"Brito","year":"2025","journal-title":"Viruses"},{"issue":"1","key":"10.1016\/bs.enz.2025.06.009_bib0085","doi-asserted-by":"crossref","DOI":"10.1080\/21505594.2024.2396484","article-title":"Pathogenicity and virulence of chikungunya virus","volume":"15","author":"Freppel","year":"2024","journal-title":"Virulence"},{"issue":"1","key":"10.1016\/bs.enz.2025.06.009_bib0086","doi-asserted-by":"crossref","first-page":"42","DOI":"10.20344\/amp.21911","article-title":"Doen\u00e7a causada por filov\u00edrus: uma atualiza\u00e7\u00e3o [disease caused by filoviruses: an update]","volume":"38","author":"Marx de Andrade","year":"2025","journal-title":"Acta. Med. Port"},{"key":"10.1016\/bs.enz.2025.06.009_bib0087","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/978-1-0716-4256-6_2","article-title":"Marburg virus medical countermeasures","volume":"2877","author":"Martins","year":"2025","journal-title":"Methods Mol. Biol"},{"issue":"10","key":"10.1016\/bs.enz.2025.06.009_bib0088","doi-asserted-by":"crossref","first-page":"e1730","DOI":"10.1016\/S2214-109X(24)00255-9","article-title":"Improving Ebola virus disease outbreak control through targeted post-exposure prophylaxis","volume":"12","author":"Hoffmann Dahl","year":"2024","journal-title":"Lancet Glob. Health"},{"issue":"8","key":"10.1016\/bs.enz.2025.06.009_bib0089","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.3390\/v16081179","article-title":"Non-ebola filoviruses: potential threats to global health security","volume":"16","author":"Munyeku-Bazitama","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/bs.enz.2025.06.009_bib0090","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107914","article-title":"Advances in drug discovery of flavivirus NS2B-NS3pro serine protease inhibitors for the treatment of Dengue, Zika, and West Nile viruses","volume":"153","author":"Jo\u00e3o","year":"2024","journal-title":"Bioorg. Chem"}],"container-title":["The Enzymes","Viral Proteases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604725000162?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1874604725000162?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T19:52:28Z","timestamp":1768938748000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1874604725000162"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"ISBN":["9780443313967"],"references-count":90,"URL":"https:\/\/doi.org\/10.1016\/bs.enz.2025.06.009","relation":{},"ISSN":["1874-6047"],"issn-type":[{"value":"1874-6047","type":"print"}],"subject":[],"published":{"date-parts":[[2025]]}}}